Telmisartan, an ARB, induces apoptosis of CC cells by reducing cell cycle-related proteins (G1 cyclin, cyclin D1, CDK4, and CDK6), which induces cell-cycle arrest and suppressing tumor growth of CC cells in vivo by inhibiting activation of EGFR and TIMP-1 [70]. Here, CDK6 is linked to cholangiocarcinoma.